The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for revolutionary treatments and impressive returns is clear, the associated risks are also considerable. Many